Acetic acid--N-[(1-{N-[14-amino-1,4,7,10,13-pentahydroxy-5-(2-methylpropyl)-2,8-di(propan-2-yl)-3,6,9,12-tetraazatetradeca-3,6,9,12-tetraen-1-ylidene]-5-hydroxy-5-iminonorvalyl}pyrrolidin-2-yl)(hydroxy)methylidene]glycine (1/1) → Larazotide

HRID 2172176ノート

反応式

HRID 2172176 の反応式
[CH3:1][CH:2]([CH2:4][C@H:5]([NH:36][C:37]([C@@H:39]([NH:43][C:44]([CH2:46][NH:47][C:48]([CH2:50][NH2:51])=[O:49])=[O:45])[CH:40]([CH3:42])[CH3:41])=[O:38])[C:6]([NH:8][C@H:9]([C:13]([NH:15][C@H:16]([C:22]([N:24]1[C@H:28]([C:29]([NH:31][CH2:32][C:33]([OH:35])=[O:34])=[O:30])[CH2:27][CH2:26][CH2:25]1)=[O:23])[CH2:17][CH2:18][C:19]([NH2:21])=[O:20])=[O:14])[CH:10]([CH3:12])[CH3:11])=[O:7])[CH3:3].CC(O)=O>O>[CH3:3][CH:2]([CH2:4][C@H:5]([NH:36][C:37]([C@@H:39]([NH:43][C:44]([CH2:46][NH:47][C:48]([CH2:50][NH2:51])=[O:49])=[O:45])[CH:40]([CH3:41])[CH3:42])=[O:38])[C:6]([NH:8][C@H:9]([C:13]([NH:15][C@H:16]([C:22]([N:24]1[C@H:28]([C:29]([NH:31][CH2:32][C:33]([OH:35])=[O:34])=[O:30])[CH2:27][CH2:26][CH2:25]1)=[O:23])[CH2:17][CH2:18][C:19]([NH2:21])=[O:20])=[O:14])[CH:10]([CH3:11])[CH3:12])=[O:7])[CH3:1]

参加物

3

反応物 1

HCID 44146842Acetic acid--N-[(1-{N-[14-amino-1,4,7,10,13-pentahydroxy-5-(2-methylpropyl)-2,8-di(propan-2-yl)-3,6,9,12-tetraazatetradeca-3,6,9,12-tetraen-1-ylidene]-5-hydroxy-5-iminonorvalyl}pyrrolidin-2-yl)(hydroxy)methylidene]glycine (1/1)

生成物 1

HCID 9810532Larazotide

試薬・触媒・溶媒 1

HCID 962Water溶媒

実験手順

Solubilities of Larazotide acetate and the corresponding chloride salt in water were tested at 20° C. after 14 hours of vigorous stirring in the presence of residual solid. Concentrations of peptide are measured by standardized HPLC. The chloride salt is more soluble than the acetate salt.

出典と根拠

ORDレコード
ord-1796805bfe664afeab2f1b5ea3d417a8
出典データセット
uspto-grants-2015_06
特許番号
US09051349B2

反応ノート

読み込み中…